SCHEMBL2262995

SCHEMBL2262995

NCC1CCC(CC(N)C(=O)O)CC1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PLG P00747 1/20 0.52
PLAT P00750 1/20 0.52
LMNA P02545 1/20 0.52
GRIN2D O15399 5/20 0.44
GRIN3B O60391 5/20 0.44
GRIN1 Q05586 5/20 0.44
GRIN2A Q12879 5/20 0.44
GRIN2B Q13224 5/20 0.44
GRIN2C Q14957 5/20 0.44
GRIN3A Q8TCU5 5/20 0.44
ANPEP P15144 2/20 0.42
ENPEP Q07075 2/20 0.42
SLC1A3 P43003 2/20 0.39
SLC1A2 P43004 2/20 0.39
SLC1A1 P43005 2/20 0.39
CYP2D6 P10635 1/20 0.39
PTGS1 P23219 1/20 0.38
SLC7A11 Q9UPY5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24520198 1.00 PLG (0.52) PLGPLATLMNAGRIN2DGRIN3B
SCHEMBL5103966 1.00 PLG (0.52) PLGPLATLMNAGRIN2DGRIN3B
SCHEMBL75670 0.91
SCHEMBL75669 0.91
SCHEMBL2380451 0.91
Hydrochloric Acid SCHEMBL21058967 0.89 ANPEP (0.46) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Hydrochloric Acid SCHEMBL21058970 0.89 ANPEP (0.46) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL11218011 0.83 ANPEP (0.42) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL5103970 0.83 CPB2 (0.45) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL24520196 0.83 CPB2 (0.45) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023275357-A1 CASPASE-2 INHIBITOR COMPOUNDS Kintsugi Therapeutics S.L. (ES) 2023-01-05 WO disclosed
EP-4112631-A1 CASPASE-2 INHIBITOR COMPOUNDS Kintsugi Therapeutics S.L. (ES) 2023-01-04 EP disclosed
EP-4015529-A1 G PROTEIN PEPTIDOMIMETICS Vrije Universiteit Brussel (BE) 2022-06-22 EP disclosed
US-8445440-B2 Dimeric IAP inhibitors NOVARTIS AG (CH) 2013-05-21 US disclosed
EP-2539333-A1 DIMERIC IAP INHIBITORS Novartis AG (CH) 2013-01-02 EP disclosed
WO-2011104266-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2011-09-01 WO disclosed
US-20110206690-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2011-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110206690-A1 DIMERIC IAP INHIBITORS XIAP, BIRC5, BIRC2 PLG 1609/4885PLAT 2622/4885LMNA 198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.